CymaBay Therapeutics SG&A Expense (Quarterly) Trends

CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)

32.48 0.00 (0.00%) USD | NASDAQ | Mar 25, 16:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.

Date	Value
December 31, 2023	19.81M
September 30, 2023	12.24M
June 30, 2023	11.58M
March 31, 2023	8.324M
December 31, 2022	7.247M
September 30, 2022	5.904M
June 30, 2022	5.878M
March 31, 2022	6.087M
December 31, 2021	6.104M
September 30, 2021	5.179M
June 30, 2021	6.521M
March 31, 2021	5.236M
December 31, 2020	5.185M
September 30, 2020	3.907M
June 30, 2020	3.21M
March 31, 2020	4.418M
December 31, 2019	4.532M
September 30, 2019	4.514M
June 30, 2019	4.529M
March 31, 2019	5.663M
December 31, 2018	4.158M
September 30, 2018	3.276M

Date	Value
June 30, 2018	3.574M
March 31, 2018	3.373M
December 31, 2017	2.894M
September 30, 2017	2.21M
June 30, 2017	3.582M
March 31, 2017	3.701M
December 31, 2016	2.839M
September 30, 2016	2.13M
June 30, 2016	2.215M
March 31, 2016	2.461M
December 31, 2015	1.796M
September 30, 2015	2.201M
June 30, 2015	2.285M
March 31, 2015	2.589M
December 31, 2014	2.332M
September 30, 2014	1.687M
June 30, 2014	1.666M
March 31, 2014	2.50M
December 31, 2013	2.091M
September 30, 2013	0.683M
June 30, 2013	1.172M
March 31, 2013	0.925M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

3.21M

Minimum

Jun 2020

19.81M

Maximum

Dec 2023

6.863M

Average

5.878M

Median

Jun 2022

SG&A Expense (Quarterly) Benchmarks